Reporting owner · CIK 0001691102

Yea Christopher

SEC Form 4 history for the last 180 days across 1 company, 9 transactions and 3 filings.

CDOCHIEF DEVELOPMENT OFFICERKalVista Pharmaceuticals, Inc.
Open-market transaction mix0% buys0 buys · 3 sales

Period: Last 180 days

Trade dates in this period: May 21, 2026 – May 27, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings3Form 4 records
Buying$00 purchases
Selling$1.02M3 sales
Net value−$1.02MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Yea Christopher transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$905kView disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$239kView disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$52.6kView disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
—View disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$63.2kView disclosure →
KALVKalVista Pharmaceuticals, Inc.
CDO
CDO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
—View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at KalVista Pharmaceuticals, Inc. on May 27, 2026 valued at $905,224.84.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 202603$0$1,021,027.61−$1,021,027.61

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$340k
Median P/S size$63.2k
Direct9
Indirect0
May 27, 2026exercise

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

6 observations · May 21, 2026 – May 27, 2026. Window ends at the latest available report, not today.

Selected observation · May 27, 2026229,918 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
May 21, 2026231,117May 26, 2026View transaction
May 22, 2026228,759May 26, 2026View transaction
May 22, 2026231,884May 27, 2026View transaction
May 26, 2026229,918May 27, 2026View transaction
May 27, 2026263,718May 29, 2026View transaction
May 27, 2026229,918May 29, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Yea Christopher Insider Activity FAQ

SEC Form 4 context

Who is Yea Christopher?

Yea Christopher is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001691102.

Which companies has Yea Christopher reported transactions for?

KalVista Pharmaceuticals, Inc.

When was Yea Christopher's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Yea Christopher's latest insider sale?

The insider reported a sale at KalVista Pharmaceuticals, Inc. on May 27, 2026 valued at $905,224.84.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.